Cipla reported strong financial results for the quarter ended March 2025, with operating profit rising by 16.85%. The company’s net sales, including other operating income, grew by 9.19% to ₹6,729.69 crore compared to the same quarter last year. Most of this revenue (95.75%) came from its pharmaceutical segment, which grew by 8.46% to ₹6,503.63 crore, while its new ventures segment saw a 35.44% rise to ₹288.48 crore.
Also See: Sterling Tools Shares Rise 6% After Deal with UK’s AEM for Magnet-Free Motor Production
Profit before interest and tax (PBIT) rose 18.91% to ₹1,518.32 crore, driven mainly by the pharmaceutical segment. Operating profit margin improved to 22.85% from 21.35%, and Cipla managed to reduce raw material and other expenses. Employee cost and purchase of finished goods remained stable.
Read More: GlaxoSmithKline Pharmaceuticals Reports 35.17% Increase in Net Profit for March 2025
Other income rose 16.10% to ₹289.46 crore, and interest expenses declined by 20.30%. Loan liabilities dropped, but inventories and debtors increased. Net profit jumped 30.12% to ₹1,221.84 crore, helped by a lower effective tax rate of 18.70%. Promoter shareholding dropped to 29.13% from 33.40%.
For the full financial year, Cipla’s total sales increased by 6.88% to ₹27,547.62 crore. Pharmaceutical sales grew by 6.46%, while the new ventures segment posted a 17.24% growth. PBIT rose nearly 15% to ₹6,882.82 crore. Notably, the new ventures segment turned profitable with a ₹10.53 crore gain compared to a loss last year. Operating profit margin improved to 25.87%, and overall cost management helped boost earnings. Net profit for the year surged 27.93% to ₹5,272.52 crore. Cipla’s investments and fixed assets increased, while loan funds and cash balances reduced slightly.
The company declared a total dividend of ₹16 per share, which includes a ₹3 special dividend to mark its 90th anniversary. Regionally, India contributed 39% of Cipla’s revenue, North America 29%, Africa 15%, Emerging Markets and Europe 13%, and APIs 3%. R\&D spending stood at ₹426 crore during the quarter, or 6.3% of sales. CEO Umang Vohra highlighted consistent progress in key markets, with strong performance in India, record U.S. revenues of \$934 million, and solid growth in Africa, Europe, and emerging markets. He emphasized future growth through investments in core brands, new product development, and regulatory improvements.
